Last reviewed · How we verify
CAPOXIRI
CAPOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and repair through multiple mechanisms to kill rapidly dividing cancer cells.
CAPOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and repair through multiple mechanisms to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer (Phase 3 development).
At a glance
| Generic name | CAPOXIRI |
|---|---|
| Also known as | Experimental |
| Sponsor | National Cancer Center Hospital East |
| Drug class | Combination chemotherapy (fluoropyrimidine + platinum agent) |
| Target | Thymidylate synthase (capecitabine); DNA (oxaliplatin cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CAPOXIRI combines capecitabine (a fluoropyrimidine prodrug converted to 5-FU) with oxaliplatin (a platinum-based alkylating agent). Capecitabine inhibits thymidylate synthase to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links to prevent replication and transcription. Together, these agents provide synergistic cytotoxic activity against colorectal and other solid tumors.
Approved indications
- Metastatic colorectal cancer (Phase 3 development)
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Hand-foot syndrome
- Peripheral neuropathy
- Anemia
Key clinical trials
- TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (PHASE3)
- CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (PHASE2)
- Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAPOXIRI CI brief — competitive landscape report
- CAPOXIRI updates RSS · CI watch RSS
- National Cancer Center Hospital East portfolio CI